AstraZeneca's new crown vaccine Vaxzevria approved in Japan for people 18 years and older

Currently, the new crown pneumonia epidemic abroad is still spreading rapidly.

Recently, AstraZeneca announced that its COVID-19 vaccine Vaxzevria (ChAdOx1-S [recombinant], formerly known as AZD1222) has been approved for emergency use in Japan for active immunization of people aged 18 and over.

Japan's Ministry of Health, Labour and Welfare (MHLW) approved Vaxzevria, based on the positive efficacy and safety of the Phase 3 clinical trial in the clinical trial project led by Oxford University in the United Kingdom, Brazil and South Africa, and the Phase I/II clinical trial in Japan Sexual data.

The Pharmaceuticals and Medical Devices Agency of Japan (PMDA) recommends that the use of Vaxzevria should be limited to adults, and given by intramuscular injection, two 0.

In Japan, Vaxzevria vaccine production is already underway, and the first batch of vaccines is expected to be available in the next few weeks.

So far, the vaccine has obtained conditional sales licenses or emergency use in more than 80 countries on six continents, and has been included in the World Health Organization (WHO) emergency use list, which has accelerated the use of COVAX facilities in as many as 142 The country’s access to vaccines.

Vaxzevria (ChAdOx1-S[recombination], formerly known as AZD1222) was co-invented by Oxford University and its spin-off company Vaccitech.

Vaxzevria can be stored, transported and handled under conventional refrigeration conditions (2-8°C/36-46°F) for at least 6 months, and can be used in existing medical environments.